Last reviewed · How we verify

Neurognostics — Portfolio Competitive Intelligence Brief

Neurognostics pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Donepezil HCI (drug) Donepezil HCI (drug) marketed Acetylcholinesterase inhibitor Acetylcholinesterase (AChE) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eisai Inc. · 1 shared drug class
  2. Ludwig-Maximilians - University of Munich · 1 shared drug class
  3. Pontificia Universidade Catolica de Sao Paulo · 1 shared drug class
  4. Second Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
  5. Shanghai Jiao Tong University School of Medicine · 1 shared drug class
  6. Shanghai Mental Health Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neurognostics:

Cite this brief

Drug Landscape (2026). Neurognostics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurognostics. Accessed 2026-05-14.

Related